OBJECTIVE: To evaluate the relations between PET Pittsburgh compound B (PiB-PET) binding (amyloid imaging) and plasma Aβ in patients with mild cognitive impairment (MCI) and similarly aged controls. METHODS: In 20 patients with MCI and 19 cognitively intact controls (case-control study), PiB binding potential (BP(nd)) was assessed in 4 regions, and total brain excluding cerebellum, referenced to cerebellar binding. The mean of plasma Aβ levels measured in duplicate was analyzed. RESULTS: Plasma Aβ42/Aβ40 ratio was decreased in MCI compared to controls (mean 0.15 SD 0.04 vs mean 0.19 SD 0.07, p = 0.03) but Aβ40 (p = 0.3) and Aβ42 (p = 0.06) levels did not differ between the 2 groups. PiB BP(nd) was increased in MCI compared to controls in the cingulate (p = 0.02), parietal (p = 0.02), and total brain (p = 0.03), but not in prefrontal cortex (p = 0.08) or parahippocampal gyrus (p = 0.07). Linear regression analyses adjusting for age, sex, and cognitive test scores showed that low Aβ42/Aβ40 ratio was associated with high cingulate, parietal, and total brain PiB binding (0.01< p ≤ 0.05). These associations between PiB binding and the Aβ42/Aβ40 ratio were strongest in PiB-positive subjects and within the MCI group. CONCLUSIONS: Though cross-sectional, the findings support the "sink" hypothesis that increased brain Aβ is accompanied by lower peripheral levels of Aβ, particularly the Aβ42/Aβ40 ratio in patients with MCI. The association between PiB binding and the plasma Aβ42/Aβ40 ratio suggests possible use of plasma Aβ combined with PiB binding as a risk biomarker with potential clinical application.
OBJECTIVE: To evaluate the relations between PET Pittsburgh compound B (PiB-PET) binding (amyloid imaging) and plasma Aβ in patients with mild cognitive impairment (MCI) and similarly aged controls. METHODS: In 20 patients with MCI and 19 cognitively intact controls (case-control study), PiB binding potential (BP(nd)) was assessed in 4 regions, and total brain excluding cerebellum, referenced to cerebellar binding. The mean of plasma Aβ levels measured in duplicate was analyzed. RESULTS: Plasma Aβ42/Aβ40 ratio was decreased in MCI compared to controls (mean 0.15 SD 0.04 vs mean 0.19 SD 0.07, p = 0.03) but Aβ40 (p = 0.3) and Aβ42 (p = 0.06) levels did not differ between the 2 groups. PiB BP(nd) was increased in MCI compared to controls in the cingulate (p = 0.02), parietal (p = 0.02), and total brain (p = 0.03), but not in prefrontal cortex (p = 0.08) or parahippocampal gyrus (p = 0.07). Linear regression analyses adjusting for age, sex, and cognitive test scores showed that low Aβ42/Aβ40 ratio was associated with high cingulate, parietal, and total brain PiB binding (0.01< p ≤ 0.05). These associations between PiB binding and the Aβ42/Aβ40 ratio were strongest in PiB-positive subjects and within the MCI group. CONCLUSIONS: Though cross-sectional, the findings support the "sink" hypothesis that increased brain Aβ is accompanied by lower peripheral levels of Aβ, particularly the Aβ42/Aβ40 ratio in patients with MCI. The association between PiB binding and the plasma Aβ42/Aβ40 ratio suggests possible use of plasma Aβ combined with PiB binding as a risk biomarker with potential clinical application.
Authors: M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris Journal: Neurology Date: 2006-08-08 Impact factor: 9.910
Authors: Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2009-02 Impact factor: 10.422
Authors: O Mawlawi; D Martinez; M Slifstein; A Broft; R Chatterjee; D R Hwang; Y Huang; N Simpson; K Ngo; R Van Heertum; M Laruelle Journal: J Cereb Blood Flow Metab Date: 2001-09 Impact factor: 6.200
Authors: Nathalie Le Bastard; Laetitia Aerts; Judith Leurs; Walter Blomme; Peter P De Deyn; Sebastiaan Engelborghs Journal: Neurochem Int Date: 2009-08-18 Impact factor: 3.921
Authors: Johan Sundelöf; Vilmantas Giedraitis; Michael C Irizarry; Johan Sundström; Erik Ingelsson; Elina Rönnemaa; Johan Arnlöv; Malin Degerman Gunnarsson; Bradley T Hyman; Hans Basun; Martin Ingelsson; Lars Lannfelt; Lena Kilander Journal: Arch Neurol Date: 2008-02
Authors: Jon B Toledo; Hugo Vanderstichele; Michal Figurski; Paul S Aisen; Ronald C Petersen; Michael W Weiner; Clifford R Jack; William Jagust; Charles Decarli; Arthur W Toga; Estefanía Toledo; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Leslie M Shaw Journal: Acta Neuropathol Date: 2011-07-30 Impact factor: 17.088
Authors: Shanker Swaminathan; Shannon L Risacher; Karmen K Yoder; John D West; Li Shen; Sungeun Kim; Mark Inlow; Tatiana Foroud; William J Jagust; Robert A Koeppe; Chester A Mathis; Leslie M Shaw; John Q Trojanowski; Holly Soares; Paul S Aisen; Ronald C Petersen; Michael W Weiner; Andrew J Saykin Journal: Alzheimers Dement Date: 2013-03-26 Impact factor: 21.566
Authors: Nicholas F Fitz; Victor Tapias; Andrea A Cronican; Emilie L Castranio; Muzamil Saleem; Alexis Y Carter; Martina Lefterova; Iliya Lefterov; Radosveta Koldamova Journal: Brain Date: 2015-10-28 Impact factor: 13.501
Authors: Martin J Lan; R Todd Ogden; Dileep Kumar; Yaakov Stern; Ramin V Parsey; Gregory H Pelton; Harry Rubin-Falcone; Gnanavalli Pradhaban; Francesca Zanderigo; Jeffrey M Miller; J John Mann; D P Devanand Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472